Success Stories: Again, Our Law Firm Helped A Postdoctoral Research Fellow to Secure EB-1A Approval in 9 Days, Now Awaits I-485 Approval

Client’s Testimonial:

“I would like to appreciate your excellent work to make it possible.”

On February 10^th, 2021, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Research Fellow in the Field of Pharmacology (Approval Notice).

General Field: Pharmacology

Position at the Time of Case Filing: Postdoctoral Research Fellow

Country of Origin: India

State of Residence at the Time of Filing: California

Approval Notice Date: February 10^th, 2021

Processing Time: 9 days (Premium Processing Requested)

Case Summary:

A postdoctoral research fellow engaged the proficient services of our law firm to help him construct an EB-1A (Alien of Extraordinary Ability) petition representing his case. In order to receive the petition approval, he was required to display his extraordinary ability. So, as he held a Ph.D. in pharmacology and many years of notable merits in the same field, also, his research has been published in some of the most impacting journals, and the applications of these methodologies are effectively endless in a variety of areas such as public health and the study of disease. Thus, we were certain of his extraordinary capabilities and started preparing his case efficiently and effectively.

To strengthen our client’s case, we detailed his research on the application of molecular biology methods to the treatment of cardiovascular and respiratory diseases and has already greatly advanced the national interest through improving field-wide methods, techniques, and tools for studying the molecular and cellular pathways involved in disease. His research addresses some of our nation’s and the world’s most pressing issues, including the global health burdens of cardiovascular disease, diabetes, and inflammatory pain.

Also, we noted the 29 peer-reviewed scientific articles and 1 patent application he published, garnered 316 citations by individual researchers in at least 32 countries, suggesting his strong background in cardiovascular disease, pharmacology, and molecular biology which has allowed his research to be original, following in his success in basically transforming research into the molecular biology of cardiovascular and respiratory diseases. This impacted other researchers widely.

Not only the intrinsic value of his research, his publication, and the citation record prove him to be one of the foremost scientists working in the pharmacology field but we also observed that he had already conducted 30 reviews for highly acclaimed journals as a peer-reviewer, thereby highlighting his surpassing hold in the field.

To corroborate his case further, we advised our client to approach a few experts in the field and request recommendation letters. Five of the well-known researchers obliged and signed for the testimonial. One of the independent advisors stated:

“[Client] possesses several key experimental and analytical skills…. His dynamic pharmacological expertise allows him to produce meaningful research on topics related to cardiology, vascular biology, drug screening, diabetes, and more. On account of the strides that he has made for the field, I am fully supportive of him and his research.”

Thanks to Premium Processing, our client achieved his EB-1A petition approval just in 9 days.
This EB-1A petition approval permits our client to partake in the final part of the green card process i.e. I-485 application. We thank our client for choosing us to represent his EB1A case as well as retaining us for his I-485. We would also like to congratulate him on this milestone.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.